Amrize Forecast, price target & analysts
Amrize Target price 2026 - Analyst rating & recommendation
Amrize Classifications & Recommendation
Amrize Price Target
| Target Price | $51.00 |
| Price | $41.61 |
| Potential | 22.57% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target Amrize 2027 . The average Amrize target price is $51.00. This is 22.57% higher than the current stock price. The highest price target is $68.25 64.02% , the lowest is $32.32 22.33% . | |
| A rating was issued by 28 analysts: 18 Analysts recommend Amrize to buy, 9 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Amrize stock has an average upside potential 2027 of 22.57% . Most analysts recommend the Amrize stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
25 Analysts have issued a sales forecast Amrize 2026 . The average Amrize sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
24 Analysts have issued an Amrize EBITDA forecast 2026. The average Amrize EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
26 Amrize Analysts have issued a net profit forecast 2026. The average Amrize net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Current Amrize Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 19 2026 |
| JP Morgan |
Neutral
➜
Neutral
|
Unchanged | Oct 13 2026 |
| Longbow Research |
➜
Buy
|
Initiated | Oct 12 2026 |
| RBC Capital |
Underperform
➜
Underperform
|
Unchanged | Oct 09 2026 |
| Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 05 2026 |
| Truist Securities |
Hold
➜
Hold
|
Unchanged | Oct 05 2026 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 02 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Oct 19 2026 |
|
Unchanged
JP Morgan:
Neutral
➜
Neutral
|
Oct 13 2026 |
|
Initiated
Longbow Research:
➜
Buy
|
Oct 12 2026 |
|
Unchanged
RBC Capital:
Underperform
➜
Underperform
|
Oct 09 2026 |
|
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Oct 05 2026 |
|
Unchanged
Truist Securities:
Hold
➜
Hold
|
Oct 05 2026 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 02 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
